研究领域（方向）：

药物及疫苗经济学评价、药物政策、卫生技术评估

个人及工作简历（个人受教育及工作经历）：

教育经历：

2014/08-2017/07香港中文大学药物经济学博士

2011/09-2014/07药事管理学硕士

2007/08-2011/07制药工程学士

工作经历：

2022/09-2023/08北京大学研究员

2020/08-至今副教授

2017/09-2020/07新讲师

社会兼职：

国家医保局药物经济学组测算专家

ISPOR中国西北分会执委会副主任委员

陕西省药品临床综合评价评审专家委员会副主任委员

陕西省药学会药物经济学专业委员会常务委员

中国疫苗行业协会疫苗经济学专业委员会委员

陕西省药学会药事管理专业委员会委员

主要科研项目

主持/参与国家自然科学基金、中国博士后科学基金面上项目、陕西省自然科学基金、基本科研业务费（教师类）、制药企业（杨森、罗氏、阿斯利康、武田制药等国内外知名药企）横向合作课题等十余项科研项目。

学术及科研成果、专利、论文

代表性科研学术论文如下：

1. Jiang M, Yao X, Li P, Fang Y, Feng L, Hayat K, Shi X, Gong Y, Peng J, Atif N. Impact of video-led educational intervention on uptake of influenza vaccine among the elderly in western China: a community-based randomized controlled trial.BMC Public Health. 2022;22(1):1128.

2. Jiang M, Gong Y, Fang Y, Yao X, Feng L, Zhu S, Peng J, Shi X. Parental Preferences of Influenza Vaccination for Children in China: A National Survey with a Discrete Choice Experiment.International Journal of Environmental Research & Public Health. 2022;19(4):2145.

3. Jiang M, Li P, Yao X, Hayat K, Gong Y, Zhu S, Peng J, Shi X, Pu Z, Huang Y, Fang Y. Preference of influenza vaccination among the elderly population in Shaanxi province, China.Human Vaccines & Immunotherapeutics. 2021;17(9):3119-3125.

4. Jiang M, Feng L, Wang W, Gong Y, Ming W, Hayat K, Li P, Gillani AH, Yao X, Fang Y. Knowledge, attitudes, and practices towards influenza among Chinese adults during the epidemic of COVID-19: A cross-sectional online survey.Human Vaccines & Immunotherapeutics. 2021;17(5):1412-1419.

5. Li P*, Hayat K*,Jiang M*, Pu Z, Yao X, Zou Y, Lambojon K, Huang Y, Hua J, Xiao H, Du F, Shi L, Zhai P, Ji W, Feng Z, Gong Y, Fang Y. Impact of video-led educational intervention on the uptake of influenza vaccine among adults aged 60 years and above in China: a study protocol for a randomized controlled trial.BMC Public Health. 2021;21(1):222.（*共同一作）

6. Jiang M, Li P, Wang W, Zhao M, Atif N, Zhu S, Fang Y. Cost-effectiveness of quadrivalent versus trivalent influenza vaccine for elderly population in China.Vaccine.2020;38(5):1057-1064.

7. Jiang M, Li P, You JH, Zheng X, Deng J, Zhao M, Feng L, Fang Y. Cost-effectiveness analysis of aspirin for primary prevention of cardiovascular events among patients with type 2 diabetes in China.PLoS One. 2019;14(12):e0224580.

8. Jiang M, Leung N, Ip M, You JHS. Cost-effectiveness analysis of ribotype-guided fecal microbiota transplantation in Chinese patients with severe Clostridium difficile infection.PLoS One. 2018, 13(7): e0201539.

9. Jiang M, You JHS. Cost-effectiveness analysis of 30-month vs 12-month dual antiplatelet therapy with clopidogrel and aspirin after drug-eluting stents in patients with acute coronary syndrome.Clinical Cardiology.2017,40(10): 789-796.

10. Jiang M, You JHS.CYP2C19LOF and GOF-guided antiplatelet therapy in patients with acute coronary syndrome: A cost-effectiveness analysis.Cardiovascular Drugs and Therapy. 2016, 31(1): 39-49.

11. Jiang M, YouJHS. Cost-effectiveness analysis of personalized antiplatelet therapy in patients with acute coronary syndrome.Pharmacogenomics. 2016, 17(7): 701-713.

12. Jiang M, You JHS. Review of pharmacoeconomic evaluation of genotype-guided antiplatelet therapy.Expert Opinion on Pharmacotherapy. 2015, 16(5): 771-779.

13. Jiang M, Zhou Z, Wu L, Shen Q, Lv B, Wang X, Yang S, Fang Y.Medicine prices, availability, and affordability in the Shaanxi Province in China: implications for the future.International Journal of Clinical Pharmacy. 2015, 37(1): 12-17.

14. Jiang M, Yang S, Yan K, Liu J, Zhao J, Fang Y. Measuring access to medicines: a survey of prices, availability and affordability in Shaanxi Province of China.PLoS One. 2013, 8(8): e70836.

15. Jiang M, You JHS.CYP2C19genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: A decision analysis.Pharmacogenetics and Genomics. 2015, 25(12): 609-617.

16. Hong D, Si L,Jiang M, Shao H, Ming W, Zhao Y, Li Y, Shi L. Cost Effectiveness of Sodium‑Glucose Cotransporter‑2 (SGLT2) Inhibitors, Glucagon‑Like Peptide‑1 (GLP‑1) Receptor Agonists, and Dipeptidyl Peptidase‑4 (DPP‑4) Inhibitors: A Systematic Review.PharmacoEconomics. 2019;37(6):777-818.

17. Fang Y, Wagner AK, Yang S,Jiang M, Zhang F, Degnan DR. Access to affordable medicines after health reform: evidence from two cross-sectional surveys in Shaanxi Province, western China.Lancet Global Health. 2013, 1(4): e227-e237.

联系方式

电子邮箱：jiangmh2017@xjtu.edu.cn

联系电话：15809267859

个人主页：https://gr.xjtu.edu.cn/web/jiangmh2017

联系地址：陕西省西安市雁塔西路76号医学部